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ABSTRACT
Question
What is the safety and efficacy of interstitial chemo-
therapy with carmustine-loaded polymers (Gliadel
wafers: MGI Pharma, Bloomington, MN, U.S.A.) in
the treatment of newly diagnosed or recurrent malig-
nant glioma (that is, glioblastoma multiforme, ana-
plastic astrocytoma, anaplastic oligoastrocytoma, and
anaplastic oligodendroglioma)?
Perspectives
Malignant glioma is the most common type of pri-
mary brain tumour in adults. In general, efficacy of
systemic therapy in this patient population has been
disappointing, and novel treatment approaches are
needed. Because several randomized controlled tri-
als (RCTs) investigating the safety and efficacy of
Gliadel are available, the Neuro-oncology Disease
Site Group of Cancer Care Ontario’s Program in Evi-
dence-Based Care decided that a systematic review
of the evidence was necessary.
Outcomes
The outcomes of interest for this review were overall
survival, adverse events, and quality of life.
Methodology
Systematic searches of the MEDLINE, EMBASE, and
Cochrane Library databases were conducted for rel-
evant evidence. Fully-published reports of RCTs com-
paring treatment with Gliadel wafers to placebo or
alternative treatment were selected for inclusion. Pro-
spective cohort studies were also included.
Results
Two RCTs that compared Gliadel to placebo in patients
with newly diagnosed malignant glioma were ob-
tained. Both RCTs reported a significant survival ben-
efit for patients who received Gliadel as compared
with patients in the control group. One RCT and one
prospective cohort study were obtained that examined
the role of Gliadel in patients with recurrent malig-
nant glioma. The RCT demonstrated a significant sur-
vival benefit for Gliadel only after adjustment for
prognostic factors, and the prospective cohort study
reported no survival benefit for Gliadel as compared
with a historical control group. All three RCTs reported
similar rates of adverse events in the treatment and
control groups. The most frequently reported adverse
events were convulsions, confusion, brain edema, in-
fection, hemiparesis, aphasia, and visual field defects.
Conclusions
Gliadel is an option for selected patients with newly
diagnosed malignant glioma where a near gross total
resection is possible. No evidence is available com-
paring Gliadel with systemic therapy, and a decision
to combine Gliadel with systemic therapy should be
made for patients individually. The patient popula-
tion that would benefit from Gliadel (age, histology,
and performance status) is unclear; further investi-
gation is needed. Gliadel is also an option for pa-
tients with surgically resectable recurrent malignant
glioma.
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1. QUESTION
What is the safety and efficacy of interstitial chemo-
therapy with carmustine-loaded polymers (Gliadel
wafers: MGI Pharma, Bloomington, MN, U.S.A.) in
the treatment of newly diagnosed or recurrent malig-
nant glioma [that is, glioblastoma multiforme (GBM),
anaplastic astrocytoma, anaplastic oligoastrocytoma,
and anaplastic oligodendroglioma]?
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Outcomes of interest for this guideline were over-
all survival, adverse events, and quality of life.
2. CHOICE OF TOPIC AND RATIONALE
Malignant glioma is the most common type of pri-
mary brain tumour in adults. Approximately 5 new
cases per 100,000 population are diagnosed each year.
The current standard treatment for malignant
glioma consists of surgical resection followed by ra-
diation therapy. On recurrence, regimens of systemic
chemotherapy delivered by the intravenous or oral
route are used. Median survival remains poor despite
refinement in surgical techniques and radiation
therapy delivery.
Nitrosoureas, especially carmustine (BCNU) and,
more recently, temozolomide, are the agents most
frequently used in systemic chemotherapy. Temozol-
omide concurrently with radiotherapy and as adju-
vant therapy has shown promising survival benefits
with low toxicity, but the clinical effectiveness of
systemic therapy in general has been disappointing.
Systemic toxicities, short half-life, and limitations in
traversing the blood–brain barrier are common prob-
lems limiting the clinical effectiveness of systemic
agents. Novel methods for treating malignant glio-
mas are needed and should be evaluated to assess
their role in this devastating disease.
Gliadel wafers represent a novel approach to the
delivery of chemotherapy in malignant glioma. Re-
currence of malignant glioma is often local, suggest-
ing a role for a regional therapy. Gliadel wafers
contain carmustine and are designed to release this
agent over a 2- to 3-week period. Gliadel wafers are
placed on the surface of the resected tumour beds in
recurrent tumours and after initial resection. Data
from phase I trials have demonstrated that Gliadel is
safe and active in selected subgroups of patients with
newly diagnosed and recurrent disease 1–3, and ran-
domized data are now available. The Neuro-oncol-
ogy Disease Site Group (DSG) felt that a systematic
review of the evidence to provide an interpretation
of the available clinical trials with respect to survival
advantage, adverse events, and quality of life was
warranted.
3. METHODS
3.1 Guideline Development
The present systematic review was originally com-
pleted in the context of developing an evidence-based
series, including a clinical practice guideline, for Can-
cer Care Ontario’s Program in Evidence-Based Care
(PEBC), using the methodology of the practice guide-
lines development cycle 4. The evidence was selected
and reviewed by members of the Neuro-oncology DSG
and by methodologists. The PEBC is editorially inde-
pendent of Cancer Care Ontario and the Ontario Min-
istry of Health and Long-Term Care. Evidence-based
series produced by the PEBC undergo periodic review
and evaluation of the literature, and new evidence is
incorporated into the original reports as appropriate.
The most recent versions of the reports can be found
on the PEBC Web site: www.cancercare.on.ca/
index_practiceGuidelines.htm.
3.2 Literature Search Strategy
A systematic search of the MEDLINE (1990 to March
2006, week 3), EMBASE (1990 to 2006, week 11),
CANCERLIT (1990 to October 2002), and Cochrane
Library (2006, Issue 1) databases was conducted. The
terms “glioma” (Medical Subject Heading) and “brain
neoplasms” were combined with the text words
“Gliadel,” “carmustine,” and “BCNU.” In addition, the
Physician Data Query clinical trials database
(www.cancer.gov/clinical_trials/) and the proceedings
of the 1997–2005 meetings of the American Society
of Clinical Oncology were searched for reports of
new or ongoing trials. Relevant articles and abstracts
were selected and reviewed, and the reference lists
from these sources were searched for additional trials.
3.3 Study Selection Criteria
Articles were selected for inclusion if they
• were fully published reports of RCTs or system-
atic reviews of RCTs comparing treatment with
Gliadel wafers to placebo or alternative treatment
in patients with malignant glioma. Prospective
cohort studies were also included.
• included results regarding the safety or efficacy
of Gliadel for patients with malignant glioma.
Articles were excluded from this systematic re-
view of the evidence if they were
• letters and editorials.
• papers published in a language other than English.
4. RESULTS
4.1 Literature Search Results
In 2000, Engelhard published a review describing the
role of interstitial BCNU chemotherapy in patients with
malignant glioma 5. The Engelhard review included
five studies, including two phase I studies 1,2, one pro-
spective cohort study with historical controls 6, and
two RCTs 7,8. Since the publication of the Engelhard
review, one large RCT evaluating the role of Gliadel in
patients with malignant glioma has been published 9.
Three RCTs 7–9 and one prospective cohort study
with historical controls 6 were eligible for inclusion
in this systematic review (Table I). A long-term fol-
low-up study 10 for one of the RCTs 9 was also included.PRACTICE GUIDELINE SERIES
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The RCTs compared patients treated with Gliadel
with patients treated with placebo, and all were sup-
ported by pharmaceutical funding. Two of the RCTs
studied patients with newly diagnosed malignant
glioma 8,9. The third RCT 7 and the prospective study 6
investigated patients with recurrent malignant glioma.
No studies comparing Gliadel with alternative treat-
ment were identified.
4.2 Outcomes
4.2.1 Efficacy
Newly Diagnosed Malignant Glioma Two RCTs com-
pared Gliadel with placebo in patients with newly
diagnosed malignant glioma 8,9. Westphal et al. 9 con-
ducted a multicentre, double-blind phase III RCT that
compared 120 patients in each study arm at the time
of surgery. The sample size was specified in advance
and based on a two-tailed log-rank test with an alpha
level of 0.05 and a power of 0.90 to detect an 18%
difference in 1-year survival between Gliadel and pla-
cebo (68% vs. 50%). The original course of the trial
was 30 months, but a long-term follow-up study was
later published, extending the follow-up to
56 months  10. Survival data for 58 patients who were
known to be alive at the end of the original trial pe-
riod were obtained retrospectively and were com-
bined with data from the original study period for
analysis. Over the 56-month period, only 1 patient
was lost to follow-up.
Westphal et al 9,10 reported that overall survival
at 1 year was 59.2% for the Gliadel patients and
49.2% for the placebo patients 10. Survival for the
Gliadel and placebo groups was 15.8% and 8.3% re-
spectively at 2 years and 9.2% and 1.7% respectively
at 3 years. The difference between the survival curves
was statistically significant [hazard ratio (HR): 0.73;
95% confidence interval (CI): 0.56 to 0.95; p = 0.018],
with a 27% reduction in risk of death for patients
receiving Gliadel as compared with those receiving
placebo. Median survival was 13.8 months in the
Gliadel arm and 11.6 months in the placebo arm (p =
0.017).
Because the high number of patients undergoing
re-operation could have confounded the results (29%
in the Gliadel arm and 25% in the placebo arm at
30 months), an analysis of the intent-to-treat popula-
tion was performed, in which patients undergoing re-
operation were censored at the time of surgery. That
analysis was performed at the end of the 30-month
study period, because no data for re-operation were
available for the 58 patients who were followed long-
term after that time point. In the resulting analysis,
patients in the Gliadel group survived longer than did
those in the placebo group (HR: 0.64; 95% CI: 0.45 to
0.92; p = 0.01), with a median survival of 64.1 weeks
as compared with 49.4 weeks 9.
Westphal et al. 9,10 also analyzed their results in
histologic subgroups. In the Gliadel arm, 101 patients
had  GBM, and in the placebo arm, 106 patients had
TABLE I Overview of studies included in this systematic review
Reference Study Patients Experimental/ Additional Re-operation Chemo- Median p Value Mortality p Value
design [n control treatment [n (%)] therapy survival hazard ratio
(% GBM)] [n (%)] (weeks) (95% CI)
Patients with newly diagnosed malignant glioma
Valtonen et al. RCT 16 (69) 3.85% BCNU Standard Subsequent NR 58.1 0.012 0.27 0.006 b
1997 8 16 (100) Placebo RT after operations 39.9 (0.11–0.68) b
surgery allowed
Westphal et al. RCT 120 (84) 3.85% BCNU EBRT (2 weeks 36 (30) a 35 (29) a 59.8 0.017 0.73 0.018
2003 9,10 120 (88) Placebo after surgery) 30 (25) a 28 (23) a 50.3 (0.56–0.95)
Patients with recurrent malignant glioma
Brem et al. RCT 110 (65) 3.85% BCNU 100% No difference 52.7% prior 31 NR 0.83 0.19
1995 7 prior RT in number of chemo (0.63–1.10)
112 (65) Placebo prior surgeries 48.2% prior 23 0.67 0.006 c
(p=0.17) chemo (0.51–0.90) c
Subach et al. Cohort 17 (100) BCNU 100% 76% prior 88% prior 58 NR NR <0.001 in
1999 6 prior RT craniotomy chemo favour
Control 45 (100) No treatment 71% prior 96% prior 97 of control
craniotomy chemo
a No data available for patients in long-term follow-up study published in 2006 9. Data presented are for the original 30-month follow-up
period. All patients receiving chemotherapy in this period also underwent re-operation. When the patients who underwent re-operation
and chemotherapy were removed from the analysis at 30 months follow-up, median survival was 64.1 weeks in the  BCNU group and
49.4 weeks in the control group (p = 0.02).
b See “Discussion” for results for patients with grade IV tumours only.
c After adjustment for prognostic factors.
GBM = glioblastoma multiforme; CI = confidence interval; RCT = randomized controlled trial; BCNU = carmustine; EBRT = external-beam radio-
therapy; RT = radiotherapy; NR = not reported; NS = nonsignificant.PERRY et al.
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GBM. For that subgroup, median survival was
13.1 months in the Gliadel arm and 11.4 months in
the placebo arm. No significant difference in survival
between the two GBM subgroups was detected (HR:
0.78; 95% CI: 0.595 to 1.03, p = 0.08) 10. When
Westphal et al. corrected for the possible imbalance
in prognostic factors (because the groups had not
originally been randomized according to histologic
subgroup), no significant survival advantage was
detected for the patients with GBM in the Gliadel arm
as compared with equivalent patients in the placebo
arm (HR: 0.78; 95% CI: 0.58 to 1.05; p = 0.10). How-
ever, the trial was not designed to detect differences
between histologic subgroups.
Valtonen et al. 8 reported the results of a small
double-blind randomized trial in which 32 patients
with newly diagnosed malignant glioma were ran-
domized to receive either Gliadel or a placebo. Ini-
tially, the trial was designed to recruit 100 patients;
however, because of difficulty obtaining Gliadel, the
trial was terminated early. An imbalance was noted
in the histologies in the two arms: 16 patients in the
placebo arm had GBM (100%) as compared with 11
patients in the Gliadel arm (69%). Valtonen et al. 8
reported a statistically significant overall survival
benefit (HR: 0.27; 95% CI: 0.11 to 0.68; p = 0.006)
and increased median survival (58.1 weeks vs.
39.9 weeks, p = 0.012) in the Gliadel arm. A sub-
group analysis of the 27 patients with grade  IV
tumours revealed a similar benefit for Gliadel in over-
all survival (HR: 0.27; 95% CI: 0.10 to 0.71; p = 0.008).
Median survival for that subgroup of patients was
53.3 weeks in the treatment arm and 39.9 weeks in
the placebo arm (p < 0.05). Those results need to be
interpreted with caution because of the small num-
ber of patients and the small variances in prognostic
factors, both of which could have significantly influ-
enced outcome.
Recurrent Malignant Glioma One RCT examined the
role of Gliadel in recurrent malignant glioma 7. Brem
et al. compared 110 patients receiving Gliadel to
112 patients receiving a placebo. Each trial arm had
a similar proportion of GBM patients: 65.5% in the
Gliadel arm and 65.2% in the placebo arm. The analy-
sis of overall treatment effect showed no significant
benefit for Gliadel (HR: 0.83; 95% CI: 0.63 to 01.10;
p = 0.19). However, once adjustment was made for
the effects of prognostic factors, the overall treatment
effect favoured Gliadel (HR: 0.67; 95% CI: 0.51 to 0.90;
p = 0.006). The median survival was 31 weeks for
the Gliadel arm and 23 weeks for the placebo arm.
Overall patient survival at 6 months was 60% in the
Gliadel arm and 47% in the placebo arm. That differ-
ence was nonsignificant (p = 0.061).
As in the RCT by Westphal et al. 9, Brem et al. 7
compared histologic subgroups in the Gliadel and
placebo arms. However, the results of these subgroup
analyses need to be interpreted with caution, because
the study was not designed to detect survival differ-
ences between subgroups. The authors reported that
6-month overall survival for GBM patients was 56%
in the Gliadel arm and 36% in the placebo arm (p =
0.020). The estimated HR showed no significant dif-
ference between treatment arms (0.81, p = 0.22), but
a benefit for Gliadel was observed after an adjust-
ment for treatment group and prognostic factors (HR:
0.67; 95% CI: 0.48 to 0.95; p = 0.02).
One prospective cohort study with a historical
control examined the role of Gliadel in patients with
recurrent malignant glioma 6. In that study, 17 pa-
tients underwent surgery for recurrent malignant
glioma and received Gliadel wafers. A cohort of
45 patients who had undergone surgery for recurrent
malignant glioma during the same time period was
retrospectively identified as a control group. The au-
thors reported median survival from diagnosis as
58 weeks for the Gliadel group and 97 weeks for the
control group. Although the authors reported no sig-
nificant difference in prognostic factors between
groups, a possible selection bias was suggested, be-
cause the patients offered Gliadel had no remaining
treatment options. Patients in the control cohort re-
ceived established adjuvant treatment. The potential
for bias in nonrandomized studies with historical
controls prevents any conclusions being drawn from
the results of the study.
4.2.2 Safety
Westphal et al. 9 reported that the number of deaths,
adverse events, and laboratory abnormalities were
high, as expected in this particular patient popula-
tion. The Gliadel arm and the placebo arm both ex-
perienced similar adverse events. The most frequently
reported adverse events among the patients receiv-
ing Gliadel were hemiplegia, convulsions, confusion,
and brain edema. The most commonly reported ad-
verse events among the patients in the placebo arm
were convulsions, confusion, brain edema, and apha-
sia. The only difference between the groups in the
Westphal et al. study 4 was that more patients in the
Gliadel arm experienced intracranial hypertension
(11 patients vs. 2 patients in the placebo arm,  p =
0.019).
Valtonen et al. 8 reported results similar to those
of Westphal et al. 9. They found that 12 patients in
the treatment group and 9 patients in the placebo
group reported adverse events. The most common
adverse events among the patients in the Gliadel
group were hemiparesis, convulsion, visual field de-
fect, and aphasia.
Brem et al. 7 also found that both groups had simi-
lar occurrences of adverse events. They found that
2% of the patients in each group developed thromb-
ocytopenia, and that 1% of the patients in the Gliadel
group developed leukopenia. Brem et al. 7 also com-
pared seizures between the groups. They found that
41 patients in the Gliadel group and 32 patients inPRACTICE GUIDELINE SERIES
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the placebo group experienced seizures (p = 0.199).
The overall incidence of serious intracranial infec-
tion was 2.2%, but this complication was more com-
mon in the Gliadel arm than in the placebo arm (3.6%
and 0.89% respectively). This difference was statis-
tically nonsignificant.
5. DISCUSSION
5.1 Newly Diagnosed Malignant Glioma
Two RCTs compared the efficacy of Gliadel with pla-
cebo in patients with newly diagnosed gliomas 8,9. In
the largest RCT to date, patients who received Gliadel
for newly diagnosed malignant glioma were reported
to have experienced a 2-month improvement in me-
dian survival as compared with patients who received
placebo (p = 0.017) 10. In addition, analysis of the sur-
vival curves revealed a significant 27% reduction in
risk of mortality for patients who received Gliadel (p =
0.018). A survival advantage with Gliadel in patients
with GBM was not detected, but the trial was not de-
signed to make comparisons between histologic sub-
groups. Because the researchers in another randomized
trial were unable to obtain sufficient Gliadel, that trial
included only 32 patients newly diagnosed with ma-
lignant glioma instead of the anticipated 100 8. Al-
though a survival benefit was reported for Gliadel in
the overall patient population and in patients with GBM,
no conclusions could be reached based on the small
number of patients enrolled.
Both studies reported similar adverse events in
the treatment and control arms. The most common
adverse events associated with Gliadel were hemiple-
gia, convulsions, confusion, and brain edema. The
most commonly reported adverse events among pa-
tients who received placebo were convulsions, con-
fusion, brain edema, and aphasia. A significantly
higher number of patients experienced intracranial
hypertension in the Gliadel arm of the Westphal trial 9.
Because neither trial included a comparison with sys-
temic therapy, the possible contrast between the ad-
verse event rates associated with interstitial
chemotherapy wafers and the rates expected with
systemic chemotherapy is unclear.
Given that the largest trial demonstrated a sur-
vival advantage in the Gliadel treatment arm, Gliadel
may be considered an option in the subgroup of pa-
tients with newly diagnosed resectable malignant
gliomas. However, the exact patient population (based
on age, histology, performance status, and so on) that
may benefit from Gliadel is unclear; further investi-
gation is needed. In addition, no comparison has been
performed between the efficacy of interstitial and
systemic chemotherapy; clinicians should therefore
review the latest evidence for the benefit of systemic
chemotherapy in patients with newly diagnosed ma-
lignant glioma.
5.2 Recurrent Malignant Glioma
One RCT compared the efficacy of Gliadel with that
of placebo in patients with recurrent glioma 7. The
overall result of that trial was negative, with no sig-
nificant survival advantage seen in the primary analy-
sis. However, a survival advantage for Gliadel was
observed in the overall patient population and in pa-
tients with GBM after adjustment for prognostic fac-
tors. Given that no subgroups had been identified
a priori, the results of the subgroup analysis of GBM
patients in that trial should be interpreted with
caution.
No survival advantage for Gliadel was detected
in the cohort study with historical controls 2, but no
conclusions can be reached because of the heteroge-
neity between patients and the potential for bias in
studies of this nature.
The positive results of the RCT 7 after adjustment
for prognostic factors suggest that Gliadel may in-
crease overall survival in some patients with recur-
rent resectable malignant glioma. Because such
patients generally have a poor outlook, any treatment
that has the potential for prolonging life without sig-
nificant adverse events should be considered an
option.
6. CONCLUSIONS
Evidence from RCTs suggests a significant survival
benefit for Gliadel as compared with placebo. Gliadel
followed by standard radiotherapy is an option for
selected patients with newly diagnosed malignant
glioma where a near gross total resection is possible;
however, most patients with malignant glioma will
be ineligible for various reasons (non-resectable
tumours or contact with the ventricular system). Simi-
larly, Gliadel is an option in patients with surgically
resectable recurrent malignant gliomas. The specific
patient population (based on age, histology, perfor-
mance status, and so on) that would benefit from
Gliadel is unclear; further investigation is needed.
A direct comparison between Gliadel and sys-
temic chemotherapy has not been undertaken; such a
study would be helpful in defining the relative roles
of this local therapy and systemic therapy. The cur-
rent standard of care for patients with newly diag-
nosed GBM is radiotherapy with concurrent and
adjuvant temozolomide. No evidence is currently
available to support the sequential combination of
Gliadel with temozolomide, and therefore a decision
to use Gliadel with subsequent temozolomide should
be made for patients individually, recognizing that
little clinical experience with this combined treatment
has accrued and that patients should be made aware
of the possibility of increased toxicity. Clinical trials
investigating the combination of Gliadel wafers with
systemic therapy are required to further clarify this
issue.PERRY et al.
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